All In Biotech

Drug Trial Radar · NCT04925479

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

A Multi-center, Open-label Study to Determine the Dose and Safety of Oral Asciminib in Pediatric Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP), Previously Treated With One or More Tyrosine Kinase Inhibitors

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

46

Actual

Start

Dec 27, 2021

Primary completion

Sep 3, 2027

Study completion Oct 2, 2031

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jun 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs. Full extrapolation of the efficacy of asciminib from adult to pediatric patients will be conducted. Full extrapolation is based on the concept that CML in the pediatric population has the same pathogenesis, similar clinical characteristics and progression pattern as in adults.

Conditions

  • Myeloid Leukemia, Philadelphia Positive

Interventions

  • Asciminib Pediatric formulation groupDrug

    Asciminib Pediatric formulation group: 1 mg film-coated granules in a size 0 capsule will be supplied, taken orally (capsules are a container for the granules and are not ingested): 10 mg (10x 1 mg film-coated granules in capsule) 15 mg (15x 1 mg film-coated granules in capsule) 30 mg (30x 1 mg film-coated granules in capsule)

  • Asciminib Adult formulation groupDrug

    Asciminib Adult formulation group: 40 mg tablets BID, taken orally. 20 mg tablets BID, taken orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Pharmacokinetic (PK) parameter: AUClastTime frame: 52 weeks
  2. Primary PK parameter: AUCtauTime frame: 52 weeks
  3. Secondary PK parameter: CmaxTime frame: 52 weeks
  4. Secondary PK parameter: TmaxTime frame: 52 weeks
  5. Secondary PK parameter: CtroughTime frame: 52 weeks

Locations

23 sites in 12 countries. Site status is shown where the registry gives one.

  • Indiana UH Riley H for CIU

    Indianapolis, Indiana

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Columbia University Medical Center New York Presbyterian

    New York, New York

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Lille, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Erlangen, Germany

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Athens, Greece

  • Novartis Investigative Site

    Genova, GE, Italy

  • Novartis Investigative Site

    Roma, RM, Italy

  • Novartis Investigative Site

    Osaka, Japan

  • Novartis Investigative Site

    Yokohama, Kanagawa, Japan

  • Novartis Investigative Site

    Shinjuku-ku, Tokyo, Japan

  • Novartis Investigative Site

    Utrecht, Netherlands

  • Novartis Investigative Site

    Wroclaw, Poland

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Chiang Mai, Thailand

  • Novartis Investigative Site

    Khon Kaen, THA, Thailand

  • Novartis Investigative Site

    Istanbul, Fatih, Turkey (Türkiye)

  • Novartis Investigative Site

    Bursa, Nilufer, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.